Hair loss is a potential but uncommon side effect of Humira (adalimumab). Hair loss wasn’t reported during the drug’s studies, but has been reported since Humira was approved for use. Humira is a ...

AbbVie's growth prospects remain strong despite the impending decline in revenue from Humira, thanks to promising alternatives Skyrizi, Rinvoq, and the recently FDA-approved Linzess. The company's ...

June 7 (Reuters) - AbbVie’s (ABBV.N), opens new tab top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The first Humira biosimilar hit the U.S. market a little ...

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved ...

Two of AbbVie's most important assets could get a lot harder to sell. Overcoming Humira's far-off patent losses has been central to AbbVie's existence for so long that it can be hard to realize ...

Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It’s prescribed to treat autoimmune conditions. TNF is a protein that plays a key role in inflammation. In ...

FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.

Blue Shield of California will purchase Idacio at $525 per dose, significantly cheaper than Humira's $2100 price, enhancing affordability for patients. Collaboration with Fresenius Kabi and Evio ...

Blue Shield of California has cut the price it will pay for a biosimilar of the drug Humira. Blue Shield will purchase the medicine used to treat certain autoimmune and inflammatory diseases, such as ...

Despite launching nearly two decades ago, worldwide sales of AbbVie's (NYSE: ABBV) lead drug, Humira still generates more revenue than most countries. As you can imagine, patent-protected exclusivity ...